US biotech company to try resurrect the clinically dead
May 4, 2016Research and Development US, bioquark, biotech, brain, central nervous system, clinically dead, dead, patients, ressurect
A US biotech firm has announced plans for a Phase I trial that will see them attempt to bring brain-dead …
Pfizer joins the race, bids for Medivation – Reports
May 4, 2016Manufacturing and Production, Research and Development, Sales and Marketing AstraZeneca, Deals, M&A, MA, Medivation, Pfizer, Sanofi
US pharma giant Pfizer (NYSE: PFE) is rumoured to have joined the list of suitors vying for the Medivation (Nasdaq: …
FDA grants priority review for Amgen leukaemia drug
May 4, 2016Research and Development, Sales and Marketing Amgen, FDA, blincyto, leukaemia, lymphoblastic leukaemia, paediatric
Amgen has announced that the US Food and Drug Administration (FDA) has granted priority review status for the supplemental Biologics …
Quintiles to merge with IMS Health
May 3, 2016Medical Communications, Research and Development, Sales and Marketing IMS Health, Quintiles, merger
IMS Health (NYSE: IMS) and Quintiles (NYSE: Q) have announced that a definitive merger agreement has been made between the …
New CFO at Mylan
May 3, 2016Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Mylan, cfo, kenneth parks
Mylan has announced the appointment of Kenneth S. Parks as its new chief financial officer, effective June 6 2016. Parks …
Google files for US patent to electronic eye lens
May 3, 2016Manufacturing and Production, Research and Development Alphabet, google, lens, patent, research
Alphabet Inc (Nasdaq: GOOG) has filed a patent application for a device that can be implanted in the eye to …
EMA recommends Biogen’s MS treatment Zinbryta
May 3, 2016Research and Development, Sales and Marketing Biogen, CHMP, EMA, daclizumab, zinbryta
The Committee for Medicinal Products for Human Use (CMHP) has recommended the granting of a marketing authorisation for Zinbryta (daclizumab) …
In-depth: MSF takes on Pfizer, GSK
May 3, 2016Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Doctors Without Borders, GSK, Pfizer, analysis, medicins sans frontieres, patents, pneumonia
Medicins Sans Frontieres (MSF) recently stepped up their campaign to make the pneumonia vaccine more available in developing countries. Appearing …
France to push for drug price control regulations at upcoming G7 summit
May 3, 2016Manufacturing and Production Drug pricing, France, drug prices, g7 summit, hollande, irreversible, medicines, pharmaceutical, prices
France will urge its fellow G7 partners to introduce strict and final new limits to control the prices of new …
Weekly Movers: Neuren Pharma, Eli Lilly, Gilead Sciences…
May 3, 2016Manufacturing and Production
Corporate result announcements remained the key focus as well as the primary drivers for stock movements this week as the …
Regeneron says trial drug for osteoarthritis pain meets primary endpoint in Phase II trials
May 3, 2016Manufacturing and Production, Research and Development Phase II, Regeneron Pharmaceuticals, drug trial, osteoarthritis, phase III
Regeneron Pharmaceuticals (Nasdaq: REGN) said mid-stage trials for its drug candidate to treat osteoarthritis pain med its primary endpoint. The …
Big investor hits back at critics as Valeant’s war of words gathers pace
May 3, 2016Manufacturing and Production, Sales and Marketing Valeant, ackman, allegations, buffett, practices, price gouging, price rises, scandal
Valeant have hit the mainstream news again after key investor Bill Ackman mounted a robust defence of the company, ruling …
Allergan launches Crestor generic in the US
May 3, 2016Manufacturing and Production, Research and Development, Sales and Marketing Allergan, AstraZeneca, Crestor, FDA, FDA Approval, cholesterol, generic, patent, patent expiry, sales
Allergan has received FDA approval on the generic version of AstraZeneca’s high cholesterol drug, Crestor (rosuvastatin), and has become the …
Mylan Q1 revenue up 17%, maintains FY view
May 3, 2016Manufacturing and Production, Sales and Marketing Financial, Mylan, Q1, results, revenue, sales
Pharma firm Mylan NV (Nasdaq: MYL) on Tuesday reported a 17% rise in first-quarter revenue and said it maintains its …
Afinitor receives EU recommendation to treat rare lung cancer
April 29, 2016Manufacturing and Production, Research and Development, Sales and Marketing Afinitor, Novartis
Novartis has received a recommendation from the Committee for Medicinal Products for Human Use at the European Medicines Agency for …
Board at Medivation unanimously reject Sanofi bid
April 29, 2016Medical Communications, Sales and Marketing Medivation, Sanofi, board, hostile, rejection, takeover
The board at Medivation has unanimously rejected the $9.8 billion takeover bid from Sanofi. They declare that Sanofi’s bid of …
Novartis’ two cancer drugs get NICE backing as combination treatment for skin cancer
April 29, 2016Medical Communications NICE, Novartis, combination therapy, regulation, skin cancer
The National Institute for Health and Care Excellence (NICE) on Friday backed a combination therapy for skin cancer comprising two …
Novo Nordisk Q1 operating profit down 10% in local currencies
April 29, 2016Medical Communications, Sales and Marketing Financial, Novo Nordisk, Q1, earnings, outlook, results
Denmark’s Novo Nordisk (NYSE: NOV) on Friday posted a 10% drop in first-quarter operating profit and said it maintains its full year …
Sanofi confirm 2016 outlook with Q1 results, EPS rises 5.3%
April 29, 2016Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing 2016, Q1, Sanofi, earnings, outlook, results
Sanofi (EPA: SAN) has confirmed its outlook for 2016 with the publication of their first quarter results, with earnings per …
AstraZeneca Q1 earnings down 12%; maintains FY view
April 29, 2016Medical Communications, Research and Development, Sales and Marketing AstraZeneca, Q!, earnings, outlook, profits, q, results
UK drugmaker AstraZeneca (LSE: AZN) on Friday reported a 12% drop in first-quarter earnings and said it plans to streamline …
Latest content
Global coalition calls for stronger government action on COPD
Global health researchers call for more equitable partnerships
Liverpool launches £20m lab for infectious disease drug discovery
Circle Health Group expands into UK laboratory operations
FibroFind appoints Professor Andrew Fisher as Chief Medical Officer
